Dr. Farrukh Abbas, MD
Hospitalist (Hospitalist Physician)
- Medicare participating
At a glance
- Years since graduation
- 16
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 252
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hospitalist Physician primary
NY license 285129 -
Internal Medicine Physician
NY license 285129
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Medical College of Virginia Hospitals Richmond, VA
- Vcu Health Tappahannock Hospital Tappahannock, VA
Medical groups
- Mcv Associated Physicians (1,807 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 252
- Services billed
- 664
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 141 | 61 |
| Test to examine how well the lungs exchange gases | 88 | 88 |
| Test to measure expiratory airflow and volume | 65 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 50 | 32 |
| Test to determine lung volumes using sensors | 48 | 48 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 35 | 34 |
| Critical care, each additional 30 minutes | 27 | 14 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 15 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Rochester, NY | 70 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Rochester, NY | 64 |
| Breztri Aerosphere (budesonide/glycopyr/formoterol) Other prescribers in Rochester, NY | 47 |
| Dupixent Pen (dupilumab) Other prescribers in Rochester, NY | 38 |
| Montelukast Sodium Other prescribers in Rochester, NY | 26 |
| Prednisone Other prescribers in Rochester, NY | 25 |
| Omeprazole Other prescribers in Rochester, NY | 23 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in Rochester, NY | 23 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Rochester, NY | 22 |
| Budesonide-Formoterol Fumarate (budesonide/formoterol fumarate) Other prescribers in Rochester, NY | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,000 in total to this clinician.
| Genzyme Corporation | $1,000 |
|---|
| Grant | $1,000 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Dec 1, 2025 | Grant | $1,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $6,387 in research payments for these studies, mostly to the institutions running them.
- The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.